First detection of kobuvirus in farm animals in Brazil and the Netherlands.

Animal kobuviruses have been described in pigs, cattle, sheep and bats in countries in Asia and Europe. The virus can be detected in fecal and serum samples of infected animals with or without diarrhea, but most of the clinical as well as epidemiological features of kobuvirus infection are still unknown. This study reports the first detection of kobuvirus in farm animals from Brazil and the Netherlands and the molecular analysis of the detected strains. In Brazil, 53% (61/115) of the pigs (suckling, weaned and sows) were shedding porcine kobuvirus in feces, while in the Netherlands 16.7% (3/18) of the tested weaned pigs were infected. Kobuviruses detected in fecal samples of pigs in Brazil showed association (p = 0.0002) with diarrhea. In pig serum, kobuvirus was detected at different ages (3, 21, 36, 60, 75, and 180 days), with an overall rate of 76.7% (23/30). The sequencing of amplicons detected in serum of pigs of different ages suggested reinfection and no persistent infection. Kobuvirus was also detected in sheep and cattle feces from Brazil and the Netherlands, respectively. Phylogenetic analyses of Brazilian and Dutch kobuviruses from pig, cattle and sheep revealed genetic variability, particularly in one strain detected in sheep feces, which was more closely related to human Aichi virus. The molecular and phylogenetic analyses performed with other published kobuvirus strains and the strains presented in this study, showed that, in most of the cases, kobuvirus seems to group according to host species, but not to geographical region of origin. The data presented in this study contribute to the comprehension of kobuvirus epidemiology and also to the molecular identification of kobuvirus strains circulating worldwide

Aspects of safety: what should be considered?

Main objectives: 1. To appreciate the core competencies and the radiographer's role as a key element to ensure patient safety at the imaging department. 2. To learn about the main concepts of patient safety related to the radiographer's professional responsibility and ethics outlines at the imaging department level from a public or private hospital or even at the private practice level. 3. To discuss ways to promote patient safety and quality in imaging

Evidence based practice in radiology: the radiographer perspective

This study is included in the exploratory-descriptive type, since it aims to analyze the applicability of knowledge and evidence based radiology by radiographers during their daily work and their academic education

Balanced scorecard performance assessment in a medical imaging department

The authors present and discuss the development of a strategic management model based on the Balanced Scorecard by Kaplan and Norton to implement in an imaging ward and the relations with Performance Measurement System that allows for the monitoring of the service's evolution, the alignment of objectives, and the evaluation of individual employees within the strategy of the ward and the hospital

Increase in ghrelin levels after weight loss in obese Zucker rats is prevented by gastric banding.

Obes Surg. 2007 Dec;17(12):1599-607. Epub 2007 Nov 30. Increase in ghrelin levels after weight loss in obese Zucker rats is prevented by gastric banding. Monteiro MP, Ribeiro AH, Nunes AF, Sousa MM, Monteiro JD, Aguas AP, Cardoso MH. Department of Anatomy and UMIB (Unit for Multidisciplinary Biomedical Research) of ICBAS (Abel Salazar Institute for the Biomedical Sciences), University of Porto, 4099-003 Porto, Portugal. [email protected] Abstract BACKGROUND: Gastric banding is thought to decrease appetite in addition to the mechanical effects of food restriction, although this has been difficult to demonstrate in human studies. Our aim was to investigate the changes in orexigenic signals in the obese Zucker rat after gastric banding. METHODS: Obese Zucker rats (fa/fa) were submitted to gastric banding (GBP), sham gastric banding fed ad libitum (sham), or sham operation with food restriction, pair-fed to the gastric banding group (sham-PF). Lean Zucker rats (fa/+) were used as additional controls. Body weight and food intake were daily recorded for 21 days after surgery when epididymal fat was weighed and fasting ghrelin and hypothalamic NPY mRNA expression were measured. RESULTS: Gastric banding in obese Zucker rats resulted in a significant decrease of cumulative body weight gain and food intake. Furthermore, gastric banded rats were leaner than Sham-PF, as expressed by a significantly lower epididymal fat weight. Ghrelin levels of gastric banded rats were not increased when compared to sham-operated animals fed ad libitum and were significantly lower than the levels of weight matched sham-PF rats (1116.9 +/- 103.3 g GBP vs 963.2 +/- 54.3 g sham, 3,079.5 +/- 221.6 sham-PF and 2,969.9 +/- 150.9 g lean rats, p < 0.001); hypothalamic NPY mRNA expression was not increased in GBP when compared to sham-operated rats. CONCLUSION: In obese Zucker rats, GBP prevents the increase in orexigenic signals that occur during caloric deprivation. Our data support the hypothesis that sustained weight loss observed after gastric banding does not depend solely on food restriction

Cystic Fibrosis At A Brazilian Center Of Excellence: Clinical And Laboratory Characteristics Of 104 Patients And Their Association With Genotype And Disease Severity

Objective: To identify the clinical, laboratory and radiographic characteristics of the cystic fibrosis patients under care at Universidade Estadual de Campinas (UNICAMP) in the last decade of the twentieth century, and to investigate the association of these characteristics with genotype and severity of the disease as measured by the Shwachman score. Methods: Descriptive, retrospective and cross-sectional study of the patients assisted at UNICAMP hospital's Cystic Fibrosis Clinic from July 1990 to July 2000. Results: One hundred and four patients were studied; 53.8% male; 93.3% Caucasian; 89.4% presented with respiratory symptoms; 59.6% presented with digestive symptoms; 5.8% had meconium ileus; 4.8% had diabetes. The mean age at onset of symptoms was 3 months, and the mean age at diagnosis was 2 years and 4 months. At diagnosis, 69.9 and 56.6% of the patients had weight and height below 10th percentile, respectively; in 10.6%, sweat chloride was < 60 mEq/l. Staphylococcus aureus was found in 80.2%, Pseudomonas aeruginosa in 76.0%, and Burkholderia cepacia in 5.2%. ΔF508 homozygosis was observed in 18.75%, whereas 62.50% of the patients were ΔF508 heterozygous. A moderate/severe Shwachman score was found in 15.7%. Eighteen patients died in that period (17.3%). The mean age at death was 7 years and 8 months; median survival after diagnosis was 18 years and 4 months. Patients who have at least one ΔF508 mutation have more frequent alterations in fecal fat levels when compared to patients who do not have this mutation (p < 0.05). There were no differences in any parameter between ΔF508 homozygous and heterozygous patients. Conclusions: The clinical and laboratory characteristics of the 104 patients studied were similar to the characteristics described for patients in other countries. Exceptions are the higher age at diagnosis and lower survival. Our results support the recommendation for early diagnosis and the need for more treatment opportunities in the population of cystic fibrosis patients. Copyright © 2004 by Sociedade Brasileira de Pediatria.805371379World Health Organization and International Cystic Fibrosis (Mucoviscidosis) Association - Implementation of cystic fibrosis services in developing countries: Memorandum from a joint WHO/ICF (M)A meeting (1997) Bulletin of the World Health Organization, 75 (1), p. 10Gibson, L.E., Cooke, R.E., A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis (1959) Pediatrics, 23, pp. 545-549Rommens, J.M., Kerem, B., Greer, W., Chang, P., Tsui, L.C., Ray, P., Rapid non radioactive detection of the major cystic fibrosis mutation (1990) Am J Hum Genet, 46, pp. 395-396(2003) 2002 Annual Data Report, , Bethesda, MarylandCamargos, P.A.M., Guimarães, M.D.C., Reis, F.J.C., Prognostic aspects of cystic fibrosis in Brazil (2000) Ann Trop Pediatr, 20, pp. 287-291(1993) Informe del Cuarto Año, p. 21. , Buenos AiresHuang, N., Schidlow, D., Szatrowski, T., Palmer, J., Laraya-Cuasay, L., Yeung, W., Clinical features, survival rate and prognostic factors in young adults with cystic fibrosis (1987) Am J Med, 2, pp. 871-879Welsh, M.J., Tsui, L.C., Boat, T.F., Beaudet, A.L., Cystic fibrosis (1995) The Metabolic and Molecular Bases of Inherited Disease. 7th Ed., pp. 3799-3876. , Scriver CR, Beaudet AL, Sly WS, Valle D. New York: McGraw-HillKerem, E., Corey, M., Kerem, B., Rommens, J.M., Markiewicz, D., Levison, H., The relationship of the most common mutation ΔF508 (1990) N Engl J Med, 323, pp. 1517-1522Borgo, G., Mastella, G., Gasparini, P., Zoranello, A., Doro, R., Pignatti, P.F., Pancreatic function and genetic ΔF508 in cystic fibrosis (1990) J Med Genet, 27, pp. 665-669Santis, G., Osborne, L., Knight, R.A., Hodson, M.E., Independent genetic determinants of pancreatic and pulmonary status in cystic fibrosis (1990) Lancet, 336, pp. 1081-1084Campbell III, P.W., Phillips III, J.A., Krishnamani, M.R., Maness, K.J., Hajinski, T.A., Cystic fibrosis: Relationship between clinical status and ΔF508 deletion (1991) J Pediatr, 118, pp. 239-241Johansen, H.K., Nir, M., Hoib, Y.N., Koch, C., Schwartz, M., Severity of cystic fibrosis in patients homozygous and heterozygous for ΔF508 mutation (1991) Lancet, 337, pp. 631-634McKone, E.F., Emerson, S.S., Edwards, K.L., Aitken, M.L., Effect of genotype on phenotype and mortality in cystic fibrosis: A retrospective cohort study (2003) Lancet, 361, pp. 1671-1676(1997) Clinical Practice Guidelines for Cystic FibrosisPark, R.W., Grand, R.J., Gastrointestinal manifestations of cystic fibrosis: A review (1981) Gastroenterology, 81, p. 1143Finkelstein, S.M., Wielinski, C.L., Elliott, G.R., Diabetes mellitus associated with cystic fibrosis (1988) J Pediatr, 112, p. 373Rosenecker, J., Eichler, I., Kuhn, L., Harms, H.K., Von De Hardt, J., Genetic determination of diabetes mellitus in Danish CF patients: Prevalence and late diabetic complications (1994) Acta Paediatr, 83, pp. 72-77Bargon, J., Rickmann, J., Jacobi, V., Straub, R., Arnemann, J., Wagner, T.O., Cystic fibrosis: Initial diagnosis in a 39 year-old patient (2000) Med Klin, 95, pp. 697-700Mitcell-Heggs, P., Mearns, M., Batten, J.C., Cystic fibrosis in adolescents and adults (1976) Quarter J Med New Series, 45, pp. 479-504Maróstica, P.J.C., (1995) Avaliação Pneumológica de Pacientes Portadores de Fibrose Cística: Sua Relação Com Grupos Genéticos, , [tese]. Porto Alegre, Universidade Federal do Rio Grande do SulDomec Espinoza, M.P.S., (1998) Fibrose Cística Em Jovens e Adultos Do Hospital Das Clínicas Da Unicamp, , [dissertação]. Campinas, Universidade Estadual de Campinas;Tauber, E., Eichler, I., Gartner, C., Halmerbauer, G., Gotz, M., Rath, R., Improvements of lung function in cystic fibrosis (2002) Pediatr Pulmonol, 33, pp. 263-268Wang, S.S., O'Leary, L.A., Fitzsimmons, S.C., Khoury, M.J., The impact of early cystic fibrosis on pulmonary function in children (2002) J Pediatr, 141, pp. 804-810Wagener, J.S., Headley, A.A., Cystic fibrosis: Current trends in respiratory care (2003) Respir Care, 48, pp. 234-245Emerson, J., Rosenfeld, M., McNamara, S., Ramsey, B., Gibson, R.L., Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis (2002) Pediatr Pulmonol, 34, pp. 91-100Bush, A., Decisions facing the cystic fibrosis clinician at the first isolation of Pseudomonas aeruginosa (2002) Paediatr Respir Rev, 3, pp. 82-88Merelle, M.E., Nagelkerke, A.F., Lees, C.M., Dezateaux, C., Newborn screening for cystic fibrosis (2001) Cochrane Database Syst Rev, 3, pp. CD001402Farrell, P.M., Li, Z., Kosorok, M.R., Laxova, A., Green, C.G., Collins, J., Bronchopulmonary disease in children with cystic fibrosis after early or delayed diagnosis (2003) Am J Respir Crit Care Med, 168, pp. 1100-1108Lee, D.S., Rosenberg, M.A., Peterson, A., Makholm, L., Hoffman, G., Laessig, R.H., Analysis of the costs of diagnosing cystic fibrosis with a newborn screening program (2003) J Pediatr, 142, pp. 617-623Siret, D., Bretaudeau, G., Branger, B., Dabadie, A., Dagorne, M., David, V., Comparing the clinical evolution of cystic fibrosis screened neonatally to that of cystic fibrosis diagnosed from clinical symptoms: A 10-year retrospective study in a French region (Brittany) (2003) Pediatr Pulmonol, 35, pp. 342-349West, S.E., Zeng, L., Lee, B.L., Kosorok, M.R., Rock, M.J., Splaingard, M.J., Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: Early detection by serology and assessment of risk factors (2002) JAMA, 287, pp. 2958-2967Oliveira, M.C., Reis, F.J., Oliveira, E.A., Colosimo, E.A., Monteiro, A.P., Penna, F.J., Prognostic factors in cystic fibrosis in a single center in Brazil: A survival analysis (2002) Pediatr Pulmonol, 34, pp. 3-10Maclusky, I., Levison, H., Cystic fibrosis (1990) Kendig's Disorders of the Respiratory Tract in Children, pp. 692-729. , Chernick V, Boat TE. Philadelphia: SaundersKerem, E., Reisman, J., Corey, M., Canny, G.J., Levison, H., Prediction of mortality in patients with cystic fibrosis (1992) N Engl J Med, 326, pp. 1187-1191Bolyard, D.R., Sexuality and cystic fibrosis (2001) Am J Matern Child Nurs, 26, pp. 39-41Kulich, M., Rosenfeld, M., Goss, C.H., Wilmott, R., Improved survival among young patients with cystic fibrosis (2003) J Pediatr, 142, pp. 631-636Doull, I.J., Recent advances in cystic fibrosis (2001) Arch Dis Child, 85, pp. 62-66Reis, F.J.C., Camargos, P.A.M., Rocha, S.F., Survival analysis for cystic fibrosis in Minas Gerais State, Brazil (1998) J Trop Pediatr, 44, pp. 329-331Farrell, P.M., Kosorok, M.R., Laxova, A., Shen, G., Nutritional benefits of neonatal screening for cystic fibrosis (1997) N Engl J Med, 337, pp. 963-969Zemel, B.S., Jawad, A.F., FitzSimmons, S., Stallings, V.A., Longitudinal relationship among growth, nutritional status and pulmonary function in children with cystic fibrosis: Analysis of the Cystic Fibrosis Foundation National Patient Registry (2000) J Pediatr, 137, pp. 374-380Schechter, M.S., Shelton, B.J., Margolis, P.A., Fitzsimmons, S.C., The association of socioeconomic status with outcomes in cystic fibrosis in the United States (2001) Am J Respir Crit Care Med, 163, pp. 1331-1337O'Connor, G.T., Quinton, H.B., Kahn, R., Robichaud, P., Maddock, J., Lever, T., Case-mix adjustment for evaluation of mortality in cystic fibrosis (2002) Pediatr Pulmonol, 33, pp. 99-105Huff, D.S., Huang, N.N., Arey, J.B., Atypical cystic fibrosis of the pancreas with normal levels of sweat chloride and minimal pancreatic lesions (1979) J Pediatr, 94, p. 237Stewart, B., Zabner, J., Shuber, A.P., Welsh, M.J., Mccray Jr., P.B., Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis (1995) Am J Respir Crit Care Med, 151, pp. 899-903Desmarquest, P., Feldman, N., Tamalat, A., Boule, M., Fauroux, B., Tournier, G., Genotype analysis and phenotypic manifestations of children with intermediate sweat chloride test results (2000) Chest, 118, pp. 1591-1597Lebecque, P., Leal, T., De Boeck, C., Jaspers, M., Cuppens, H., Cassiman, J., Mutations of the cystic fibrosis gene and intermediate sweat chloride levels in children (2002) Am J Respir Crit Care Med, 165, pp. 757-761Rosentein, B.J., Cuting, G.R., The diagnosis of cystic fibrosis: A consensus statement (1998) J Pediatr, 132, pp. 589-595. , Cystic Fibrosis Foundation Consensus PanelRosentein, B.J., What is a cystic fibrosis diagnosis? (1998) Clin Chest Med, 19, pp. 423-441Ratjen, F., Döring, G., Cystic fibrosis (2003) Lancet, 361, pp. 681-689Burns, J.L., Gibson, R.L., Mcnamara, S., Yim, D., Emerson, J., Rosenfeld, M., Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis (2001) J Infect Dis, 183, pp. 444-452Dornelas, E.C., Fernandes, M.I.M., Galvão, L.C., Silva, G.A., Estudo do quadro pulmonar de pacientes com fibrose cística (2000) J Pediatr, 76, pp. 295-299. , Rio JSoni, R., Marks, G., Henry, D.A., Robison, M., Moriaty, C., Parsons, S., Effects of Burkholderia cepacia infection in the clinical course of patients with cystic fibrosis: A pilot study in a Sydney clinic (2002) Respirology, 7, pp. 241-245Jones, A.M., Dodd, M.E., Webb, A.K., Burkholderia cepacia: Current clinical issues, environmental controversies and ethical dilemmas (2001) Eur Respir J, 17, pp. 295-301Lewin, L.O., Byard, P.J., Davis, P.B., Effect of Pseudomonas cepacia colonization on survival and pulmonary function of cystic fibrosis patients (1990) J Clin Epidemiol, 43, pp. 125-131Speert, D.P., Henry, D., Vandamme, P., Corey, M., Mahenthiralingam, E., Epidemiology of Burkholderia cepacea complex in patients with cystic fibrosis, Canada (2002) Emerg Infec Dis, 8, pp. 181-187Raskin, S., Philips III, J.A., Krishnamani, M.R.S., Jones, C., Parker, R.A., Rozov, T., DNA analysis of cystic fibrosis in Brazil by direct PCR amplification from guthrie cards (1993) Am J Med Gen, 46, pp. 665-669Cystic Fibrosis Genetic Analysis Consortium - Population variation of common cystic fibrosis mutations (1994) Human Mutation, 4, pp. 167-177Guilloud-Batalie, M., De Crozes, D., Rault, G., Degioanni, A., Feingold, J., Cystic fibrosis mutations: Report from the French Registry (2000) Hum Hered, 50, pp. 142-145. , The Clinical Centers of the CFSaleh, M.C., Botelli, A., Melano De Botelli, M., Rezzonico, C.A., Argaraña, C.E., Cystic fibrosis: Frequency of delta F508 and G542X mutations in Cordoba, Argentina (1996) Medicina, 56, pp. 14-16. , B. AiresVillarreal, M.T., Chavez, M., Lezana, J.L., Cuevas, F., Carnevale, A., Codova, E., G542X mutation in Mexican cystic fibrosis patients (1996) Clin Genet, 49, pp. 54-56Henry, R.L., Mellis, C.M., Petrovic, L., Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis (1992) Pediatr Pulmonol, 12, pp. 158-161Assis, I., Camargos, P.A.M., Reis, F.J.C., Sulmonett, N., Carneiro, A.P.S., Assessing correlations between spirometry and Shwachman-Kulczycki score in children and adolescents (2003) Pediatr Pulmonol, 36, pp. 305-309Farrell, P.M., Koscik, R.E., Sweat chloride concentrations in infants homozygous or heterozygous for ΔF508 cystic fibrosis (1996) Pediatrics, 97, pp. 524-52

Pulsed Direct And Constant Direct Currents In The Pilocarpine Iontophoresis Sweat Chloride Test

Background: The classic sweat test (CST) is the golden standard for cystic fibrosis (CF) diagnosis. Then, our aim was compare the production and volume of sweat, and side effects caused by pulsed direct current (PDC) and constant direct current (CDC). To determine the optimal stimulation time (ST) for the sweat collection. To verify the PDC as CF diagnosis option. Methods: Prospective study with cross-sectional experimental intervention. Experiment 1 (right arm): PDC and CDC. ST at 10 min and sweat collected at 30 min. Currents of 0.5; 0.75; 1.0 and 1.5 mA and frequencies of 0, 200, 1,000 and 5,000 Hz applied. Experiment 2 (left arm): current of 1.0 mA, ST at 5 and 10 min and sweat collected at 15 and 30 min with frequencies of 0; 200; 1,000 and 5,000 Hz applied Experiments 1 and 2 were performed with current density (CD) from 0.07 to 0.21 mA/cm2. Experiment 3: PDC was used in typical CF patients with two CFTR mutations screened and or with CF diagnosis by rectal biopsy and patients with atypical CF. Results: 48 subjects (79.16% female) with average of 29.54 ± 8.87 years old were enrolled. There was no statistical difference between the interaction of frequency and current in the sweat weight (p = 0.7488). Individually, positive association was achieved between weight sweat and stimulation frequency (p = 0.0088); and current (p = 0.0025). The sweat production was higher for 10 min of stimulation (p = 0.0023). The sweat collection was better for 30 min (p = 0.0019). The skin impedance was not influenced by ST and sweat collection (p &gt; 0.05). The current frequency was inversely associated with the skin impedance (p &lt; 0.0001). The skin temperature measured before stimulation was higher than after (p &lt; 0.0001). In Experiment 3 (29 subjects) the PDC showed better kappa index compared to CDC (0.9218 versus 0.5205, respectively). Conclusions: The performance of the CST with CDC and PDC with CD of 0.14 to 0.21 mA/cm2 showed efficacy in steps of stimulation and collection of sweat, without side effects. The optimal stimulation time and sweat collection were, respectively, 10 and 30 min.141Di Sant'S Agnese, P.A., Darling, R.C., Perara, G.A., Shea, E., Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas (1953) Am J Dis Child, 86, pp. 618-619Gibson, L.E., Cooke, R.E., A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis (1959) Pediatrics, 23, pp. 545-549Taylor, C.J., Hardcastle, J., Southern, K.W., Physiological measurements confirming the diagnosis of cystic fibrosis. The sweat test and measurements of transepithelial potential difference (2009) Paedia Resp Rev, 10, pp. 220-226Rosenstein, B.J., What is a cystic fibrosis diagnosis? (1998) Clin Chest Med, 19, pp. 423-441Rowe, S.M., Miller, S., Sorscher, E.J., Cystic fibrosis (2005) N Engl J Med, 352, pp. 1992-2001Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation Consensus Report (2008) J Pediatr, 153, pp. S4-e14Castellani, C., Southern, K.W., Brownlee, K., DankertRoelse, J., Duff, A., Farrell, M., Mehta, A., Elborn, S., European best practice guidelines for cystic fibrosis neonatal screening (2009) J Cystic Fibrosis, 8, pp. 153-173Quinton, P.M., Cystic fibrosis: lesson from the sweat gland (2007) Physiology (Bethesda), 22, pp. 212-225Quinton, P.M., Chloride impermeability in cystic fibrosis (1983) Nature, 301, pp. 421-422Collie, J.T.B., Massie, R.J., Jones, O.A.H., LeGrys, V.A., Greaves, R.F., Sixty-Five Years Since the New York Heat Wave: Advances in Sweat Testing for Cystic Fibrosis (2014) Pediatr Pulmonol, 49, pp. 106-117Legrys, V.A., Sweat testing for the diagnosis of cystic fibrosis. Practical considerations (1996) J Pedia, 129, pp. 892-897Gonçalves, A.C., Marson, F.A.L., Mendonça, R.M.H., Ribeiro, J.D., Ribeiro, A.F., Paschoal, I.A., Levy, C.E., Saliva as a potential tool for cystic fibrosisdiagnosis (2013) Diagn Pathol, 8, p. 46Webster, H.L., A clinical appraisal of cystic fibrosis sweat-testing guidelines (2001) Am Clin Lab, 20, pp. 39-42Hammond, K.B., Nelson, L., Gibson, L.E., Clinical evaluation of the macroduct sweat collection system and conductivity analyzer in the diagnosis of cystic fibrosis (1994) J Pediatr, 124, pp. 255-260Portaria N° 288, 21 de Março de 2013. Diário oficial da união, Brasília, N° 56 - DOU - 22/03/13 - seção 1 , p. 47. , ftp://ftp.saude.sp.gov.br/ftpsessp/bibliote/informe_eletronico/2013/iels.mar.13/Iels55/U_PT-MS-SAS-288_210313.pdf, BrasilNumajiri, S., Sakurai, H., Sugibayashi, K., Morimoto, Y., Omiya, H., Takenaka, H., Akiyama, N., Comparison of depolarizing and direct current systems on iontophoretic enhancement of transport of sodium benzoate through human and hairless rat skin (1993) J Pharm Pharmcol, 45, pp. 610-613Zakzewski, C.A., Amory, D.W., Jasaitis, D.K., Li, J.K.J., Iontophoretically enhanced transdermal delivery of an ACE inhibitor in induced hypertensive rabbits: preliminary report (1992) CardiovascularDrugs and Therapy, 6, pp. 589-595Bagniefski, T.M., Burnette, R.R., A comparison of pulsed and continuous current iontophoresis (1990) J Cont Release, 11, pp. 113-122Preat, V., Thysman, S., Trandermaliontophoreric delivery of sulfentanilInt (1993) J Pharmaceut, 96, pp. 189-196(2000) Obesity: Preventing and managing the global epidemic, , Geneva: World Health Organization Technical Support Series, 894, Geneva: World Health OrganizationSousa, M., Servidoni, M.F., Vinagre, A.M., Ramalho, A.S., Bonadia, L.C., Felício, V., Ribeiro, M.A., Amaral, M.D., Measurements of CFTR-mediated Cl- secretion in human rectal biopsies constitute a robust biomarker for Cystic Fibrosis diagnosis and prognosis (2012) Plos One, 7, p. e47708Carlsson, A.M., Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale (1983) Pain, 16, pp. 87-101Rosenstein, B.J., Cutting, G.R., The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel (1998) J Pediatr, 132, pp. 589-595Karezeski, B., Cutting, G., Diagnosis of cystic fibrosis. CFTR-related disease and screening (2006) ProgRespir Res, 34, pp. 69-76Strausbaugh, S.D., Davis, P.B., Cystic fibrosis: a review of epidemiology and pathobiology (2007) Clin Chest Med, 28, pp. 279-288Mackay, R., George, P., Kirk, J., Sweat testing for cystic fibrosis: A review of New Zealand laboratories (2006) J Paedia Child Health, 42, pp. 160-164Cirilli, N., Podan, R., Raia, V., Audit of sweat testing: A first report from Italian cystic fibrosis centres (2008) J Cystic Fibrosis, 7, pp. 415-422Kirk, J.M., Inconsistencies in sweat testing in UK laboratories (2000) Arch Dis Child, 82, pp. 425-427Webster, H.L., Laboratory diagnosis of cystic fibrosis (1983) CRC Crit Rev in Clin LabSci, 18, pp. 313-338http://www.wescor.com/biomedical/cysticfibrosis/macroduct.htmlSabbahi, M.A., Costello, C.T., Ernran, A., A method for reducing skin irritation by iontophoresis (1994) PhysTher, 74, p. S156Su, M.H., Srinivasan, V., Ghanem, A.H., Higuchi, W.I., Quantitative in vivo iontophoreticstudies (1994) J Pharm Sci, 83, pp. 12-17Huang, Y.-Y., Wu, S.-M., Transdermal Iontophoretic Delivery of Thyrotropin-Releasing Hormone Across Excised Rabbit Pinna Skin Drug Dev (1996) Ind Pharm, 22, pp. 1075-1081Knoblauch, P., Moll, F., In vitro pulsatile and continuous transdermal delivery of buserelin by iontophoresis (1993) J Control Release, 26, pp. 203-212Okabe, K., Yamaguchi, H., Kawai, Y., New iontophoretic transdermal administration of the beta-blocker metoprolol (1986) J Control Release, 4, pp. 79-85Li, S.K., Higuchi, W.I., Zhu, H., Kern, S.E., Miller, D.J., Hastings, M.S., In vitro and in vivo comparisons of constant resistance AC iontophoresis and DC iontophoresis (2003) J Control Release, 91, pp. 327-343Banga, A.K., Chien, Y.W., Iontophoretic delivery of drugs: fundamentals, developments and biomedical application (1988) J Control Rel, 7, p. 1Panzade, P., Heda, A., Puranik, P., Patni, M., Mogal, V., Enhanced Transdermal Delivery of Granisetron by Using Iontophoresis (2012) IJPR, 11, pp. 503-512Chen, L.L.H., Chien, Y.W., Transdermal iontophoretic permeation of luteinizing hormone releasing hormone: characterization of electric parameters (1996) J Control Release, 40, pp. 187-198Chien, Y.W., Siddiqui, O., Shi, W.M., Lelawongs, P., Liu, J.C., Direct current iontophoretic transdermal delivery of peptide and protein drugs (1989) J Pharm Sci, 78, pp. 376-383Hirvonen, J., Hueber, F., Guy, R.H., Current profile regulates iontophoretic delivery of amino acids across the skin (1995) J Control Release, 37, pp. 239-249Kanebako, M., Inagi, T., Takayama, K., Transdermal delivery of iondomethacin by iontophoresis (2002) Biol Pharm Bull, 25, pp. 779-782Abramowitz, D., Neoussikine, B., (1946) Treatment by Ion Transfer, p. 87. , NewYork: Grune and StrattonLeGrys, V.A., Applequist, R., Briscoe, D.R., Farrell, P., Hickstein, R., Lo, S.F., Passarell, R., Vaks, J.E., Sweat testing: sample collection and quantitative chloride analysisapproved guidelines - Third Edition (2009) Clin Lab Stand Ins, 29. , C34-A2Beauchamp, M., Lands, L.C., Sweat-Testing: A Review of Current Technical Requirements (2005) Pediatr Pulmonol, 39, pp. 507-511Chiang, C.H., Shao, C.H., Chen, J.L., Effects of pH electric current, and enzyme inhibitors on iontophoresis of delta sleep-inducing peptide (1998) Drug Dev Ind Pharm, 24, pp. 431-438Van der Geest, R., Banhof, M., Bodde, H.E., Iontophoretic delivery of apomorphine I. In-vitro optimization and validation (1997) Pharm Res, 14, pp. 1798-1803Heap, S., Guidelines for the Performance of the Sweat Test for the Investigation of Cystic Fibrosis in the UK 2nd Version. An Evidence Based Guideline (2014) R College Paediatr Child Health, 2, pp. 1-121Kalia, Y.N., Naik, A., Garrison, J., Guy, R.H., Iontophoretic drug delivery (2004) Adv Drug DelivVer, 56, pp. 619-658Barry, B.W., Drug delivery routes in skin: a novel approach (2002) Adv Drug Deliv Rev, 54, pp. S31-S40Pikal, M.J., The role of electroosmotic flow in transdermal iontophoresis (1992) Adv Drug Deliv Rev, 9, pp. 201-237Curdy, C., Kalia, Y.N., Guy, R.H., Post-iontophoresis recovery of human skin impedance in vivo (2002) Eur J Pharm Biopharm, 53, pp. 15-21Ulreich, A., Leibrecht, W., Promer, M., Kullich, W., Infiltration versus iontophoresis in case of epicondylitis. A comparative study. Physikalische Medizin Rehabilitations medizin (1996) Kurortmedizin, 6, pp. 183-185Bolfe, V.J., Ribas, S.I., Montebelo, M.I.L., Guirro, R.R.J., Comportamento da impedância elétrica dos tecidos biológicos durante a estimulação elétrica transcutânea (2007) Rev Bras Fisioter, 11, pp. 153-159Bioelectrical impedance analysis-part I: review of principles and methods (2004) ClinNutr, 23, pp. 1226-1243Nakakura, M., Kato, Y., Hayakawa, E., Kuroda, T., Effect of pulse on iontophoretic delivery of desmopressin acetate in rats (1996) Biol Pharm Bull, 19, pp. 738-740Sagi-Dolev, A.M., Prutchi, D., Nathan, R.H., Three-dimensional current density distribuition under surface stimulation electrodes (1995) Med Biol Eng Comp, 33, pp. 403-408Zhu, F., Scheditz, D., Levin, N.W., Estimation of trunk extracellular volume by bioimpedance (1998) Conf Proc IEEE Eng Med Biol Soc, 20, pp. 3104-3107Chizmadzhev, Y.A., Kuzmin, P.I., Weaver, J.C., Potts, R.O., Skin appendageal macropores as a possible pat way for electrical current (1998) J Investg Dermatol Symp Proc, 3 (2), pp. 148-152Ya-Xian, R.O., Suetake, T., Tagami, H., Number of cell layers of the stratum corneum in normal skin-relationship to the anatomical location on the body, age, sex and physical parameters (1999) Arch Dermatol Res, 291, pp. 555-559Nelson, R.M., Hayes, K.W., Currier, D.P., (1999) Clinical Electrotherapy, pp. 15-54. , 3a. ed. Stanford: Appleton & LangeLow, J., Reed, A., (2000) Electrotherapy Explained: Principles and Practice, , Oxford: Butterworth-HeinemannCameron, M.H., (1999) Physical Agents in Rehabilitation: From Research to Practice, , Philadelphia: W.B.Saunders companyKubisz, L., The influence of storage time on the temperature dependence of the dc electrical conductivity of horn kereatin (2001) Bioelectrochemistry, 53, pp. 161-16

On the consistency of the three-dimensional noncommutative supersymmetric Yang-Mills theory

We study the one-loop quantum corrections to the U(N) noncommutative supersymmetric Yang-Mills theory in three spacetime dimensions (NCSYM$_3$). We show that the cancellation of the dangerous UV/IR infrared divergences only takes place in the fundamental representation of the gauge group. Furthermore, in the one-loop approximation, the would be subleading UV and UV/IR infrared divergences are shown to vanish.Comment: 8 pages and 2 figure